On August 27, AKESO rose 3.03% in regular trading, trading at 97.65 HKD/share, with turnover of HKD 175 million.

On the news front, the company announced on August 26 that its PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy achieved the primary endpoint of overall survival in the Phase 3 HARMONi-GI1 trial for first-line treatment of advanced biliary tract cancer, demonstrating statistically significant and clinically meaningful superiority over durvalumab plus chemotherapy. Key secondary endpoints of progression-free survival and objective response rate were also met. The study enrolled 682 patients and represents the first Phase 3 trial in biliary tract cancer to show significant OS improvement over the global standard of care, marking ivonescimab's expansion from lung cancer into gastrointestinal tumors.

Additionally, the company's board is scheduled to review and release interim results on August 27, providing further near-term catalyst. Ivonescimab's third indication was approved on August 12 for first-line squamous NSCLC, with commercial ramp trajectory drawing market attention.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)